Misses from amyotrophic lateral sclerosis hopefuls Denali Therapeutics and partners AbbVie and Calico Life Sciences mark the ...

Denali Therapeutics Inc.'s stock remains stable despite trial setback in ALS. BLA filing for MPS II treatment on track. Click ...

Denali Therapeutics Inc. (NASDAQ:DNLI) revealed topline results from an analysis of Regimen G of the Phase 2/3 HEALEY ALS ...

A renowned Israeli TV journalist who lost his ability to speak clearly because of ALS is returning to the air using ...

When a renowned Israeli TV journalist lost his ability to speak clearly because of ALS, he thought his career might be over.

目前，为了帮助像王先生一样的渐冻人，也为了减轻看护者的负担，商汤科技开发出一款渐冻人AI看护系统，获得了社会关注。当前，该项目已获得上海市互联网联合会发起的2024年社会责任和社会公益优秀案例奖。

Channel 12 made the surprising announcement that it would bring Nussbaum back on the air in the coming weeks as a commentator ...

Denali’s failure on Monday continues biopharma’s losing streak against amyotrophic lateral sclerosis. PTC Therapeutics and ...

NX-210c is under clinical development by Axoltis Pharma and currently in Phase I for Amyotrophic Lateral Sclerosis. According to GlobalData, Phase I drugs for Amyotrophic Lateral Sclerosis have an 81% ...

The voice of Israeli journalist Moshe Nussbaum has been revived using artificial intelligence after he was diagnosed with ALS.

Acetylcysteine zidrimer is under clinical development by Orpheris and currently in Phase II for Amyotrophic Lateral Sclerosis.